Stockscreener 앱 받기
8.155
1.68%
0.135
시간 외 거래:
8.16
0.005
+0.06%
전일 마감가:
$8.02
열려 있는:
$8.02
하루 거래량:
648.71K
Relative Volume:
0.78
시가총액:
$538.64M
수익:
$301.79M
순이익/손실:
$-43.42M
주가수익비율:
-12.16
EPS:
-0.6705
순현금흐름:
$-44.87M
1주 성능:
+7.44%
1개월 성능:
+30.06%
6개월 성능:
+89.65%
1년 성능:
+27.42%
1일 변동 폭
$7.91
$8.258
1주일 범위
$7.18
$8.43
52주 변동 폭
$3.86
$8.43
Evolus Inc Stock (EOLS) Company Profile
명칭
Evolus Inc
전화
(949) 284-4555
주소
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
8.155 | 536.33M | 301.79M | -43.42M | -44.87M | -0.6705 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 다운그레이드 | Needham | Buy → Hold |
| 2025-04-17 | 개시 | BTIG Research | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 개시 | Needham | Buy |
| 2022-05-12 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-04-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-24 | 다운그레이드 | Truist | Buy → Hold |
| 2020-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-02-06 | 재개 | Mizuho | Buy |
| 2019-11-26 | 개시 | SVB Leerink | Outperform |
| 2019-09-05 | 재개 | Mizuho | Buy |
| 2019-06-28 | 개시 | Wells Fargo | Market Perform |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
모두보기
Evolus Inc 주식(EOLS)의 최신 뉴스
August 2026's Leading Growth Companies With Insider Confidence - Sahm
Midday Stock Roundup: Mobix Labs Shares Fall 21% at Midday - Orange County Business Journal
Renaissance Technologies LLC Lowers Stake in Evolus, Inc. $EOLS - marketbeat.com
Evolus, Inc. (EOLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS - marketbeat.com
Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evolus (NASDAQ:EOLS) Reaches New 1-Year HighHere's What Happened - MarketBeat
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade - Yahoo Finance
Evolus: The Injectable Platform Is Becoming The Real Moat (NASDAQ:EOLS) - Seeking Alpha
Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Trading Systems Reacting to (EOLS) Volatility - Stock Traders Daily
Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen - marketbeat.com
Needham Maintains Evolus(EOLS.US) With Hold Rating - moomoo.com
BTIG Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Evolus Inc (EOLS) Stock News Today - TradingKey
Evolus, Inc. (EOLS) Investor Outlook: Analyzing 97.93% Potential Upside in the Aesthetic Market - DirectorsTalk Interviews
Stifel Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Su - GuruFocus
Evolus, Inc. Q2 2026 Financial Results: Revenue, Risks, and Key Business Updates - Minichart
Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ... - Yahoo Finance
Earnings call transcript: Evolus tops revenue forecast in Q2 2026, shares rise - Investing.com South Africa
Evolus Q2 Earnings Call Highlights - MarketBeat
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2 - Yahoo Finance
Is Evolus Inc (EOLS) Undervalued After Q2 Earnings Beat? EPS: -0 - GuruFocus
Evolus Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Evolus Q2 2026 slides: profitability streak continues, guidance raised - Investing.com
Evolus, Inc. Q2 2026: Revenue $84.08M, EPS ($0.12) — 10-Q Summary - TradingView
Evolus (EOLS) Releases Q2 2026 Earnings: Revenue Growth and Narrower Losses - Quiver Quantitative
Evolus (Nasdaq: EOLS) posts higher sales and manages sizable debt load - stocktitan.net
Evolus Q2 revenue rises 21%, lifts 2026 outlook - TradingView
Evolus Q2 2026 Earnings: Revenue Rises 21% as Adjusted EBITDA Stays Positive - TradingKey
Evolus (NASDAQ: EOLS) lifts 2026 guidance after Q2 revenue hits $84.1 million - Stock Titan
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook - marketscreener.com
Evolus, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Evolus (NASDAQ:EOLS) Posts Earnings Results, Misses Expectations By $0.08 EPS - marketbeat.com
Evolus Deadline Alert - TMX Newsfile
Evolus Expands Symatese Partnership into Three New Markets - Orange County Business Journal
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme in Canada, Australia, and New Zealand - marketscreener.com
Evolus expands hyaluronic acid gel rights to three markets By Investing.com - Investing.com Nigeria
Evolus expands hyaluronic acid gel rights to three markets - Investing.com
Evolus, Inc. (NASDAQ: EOLS) extends Estyme deal to $500M markets - Stock Titan
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand - Yahoo Finance
Evolus Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Perceptive Advisors LLC Acquires New Stake in Evolus, Inc. $EOLS - marketbeat.com
Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com
Evolus (EOLS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Evolus Inc (EOLS) Balance Sheet - TradingKey
Evolus Inc (EOLS) Income Statement - TradingKey
Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EOLS|Evolus Inc|Price:5.980|Chg%:-0.010 - TradingKey
Evolus Inc (EOLS) Institutional Confidence - TradingKey
Evolus Inc (EOLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
5.15%
자본화:
|
볼륨(24시간):